MERCK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - MRK

Core Viewpoint - The article discusses a class action lawsuit against Merck & Co., Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's revenue outlook and the performance of its Gardasil product during the class period from February 3, 2022, to February 3, 2025 [1][3]. Summary by Sections Class Action Lawsuit Details - The lawsuit, titled Cronin v. Merck & Co., Inc., allows purchasers of Merck securities during the specified class period to seek appointment as lead plaintiff by April 14, 2025 [1][2]. - Allegations include that Merck executives misrepresented the company's revenue outlook and downplayed competition risks related to Gardasil, particularly in China [3]. Financial Impact and Stock Performance - On July 30, 2024, Merck disclosed a significant drop in shipments from its distributor, leading to a nearly 10% decline in stock price [4]. - Following the release of fourth quarter fiscal year 2024 results on February 4, 2025, which reported a 3% decline in Gardasil sales to $8.6 billion, Merck's stock fell over 9$6.6 billion for investors in class action cases, making it a leader in the field [7].